E Fund Management Co. Ltd. Raises Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

E Fund Management Co. Ltd. raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 151.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,761 shares of the biotechnology company’s stock after buying an additional 5,276 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Sarepta Therapeutics were worth $1,384,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Principal Securities Inc. acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at about $26,000. Dimensional Fund Advisors LP grew its stake in shares of Sarepta Therapeutics by 10.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock valued at $21,621,000 after purchasing an additional 20,923 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 125.3% in the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock valued at $4,777,000 after buying an additional 27,549 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Sarepta Therapeutics by 65.2% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,108 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 1,227 shares during the period. Finally, Norges Bank acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $80,697,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $125.69 on Wednesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25. The firm has a market cap of $11.88 billion, a price-to-earnings ratio of 1,142.64 and a beta of 0.81. The firm’s 50-day simple moving average is $139.24 and its 200 day simple moving average is $132.69.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue was up 38.9% compared to the same quarter last year. During the same period last year, the company earned ($0.27) EPS. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRPT has been the subject of several research reports. Bank of America lifted their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Citigroup reduced their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Leerink Partners upped their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Finally, Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their price objective for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $187.39.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.